Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott E Strome

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
Cancer Immunology, Immunotherapy : CII|December 25, 2014
A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)Dan P Zandberg, Sandra Rollins, Olga Goloubeva, et al.
Cancer|December 2, 2016
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning MeetingJulie E Bauman, Ezra Cohen, Robert L Ferris, et al.
Nature Communications|October 16, 2015
RFX transcription factors are essential for hearing in miceRan Elkon, Beatrice Milon, Laura Morrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2014
Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cellsAaron P Rapoport, Nicole A Aqui, Edward A Stadtmauer, et al.
Cell Reports. Medicine|March 20, 2024
DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinomaAllison M Kirk, Jeremy Chase Crawford, Ching-Heng Chou, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
Cancer Immunology, Immunotherapy : CII|December 25, 2014
A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)Dan P Zandberg, Sandra Rollins, Olga Goloubeva, et al.
Cancer|December 2, 2016
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning MeetingJulie E Bauman, Ezra Cohen, Robert L Ferris, et al.
Nature Communications|October 16, 2015
RFX transcription factors are essential for hearing in miceRan Elkon, Beatrice Milon, Laura Morrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2014
Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cellsAaron P Rapoport, Nicole A Aqui, Edward A Stadtmauer, et al.
Cell Reports. Medicine|March 20, 2024
DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinomaAllison M Kirk, Jeremy Chase Crawford, Ching-Heng Chou, et al.
Pageof 9